PGO0 Stock Chart & Stats
€0.05
-€0.02(-2.92%)
At close: 4:00 PM EST
€0.05
-€0.02(-2.92%)
Day’s Range― - ―
52-Week Range<€0.01 - €0.05
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€7.76M
Enterprise Value€12.73M
Total Cash (Recent Filing)€9.07M
Total Debt (Recent Filing)€5.30M
Price to Earnings (P/E)―
Beta-1.41
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.82
Shares Outstanding532,703,900
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.38
Price to Sales (P/S)17.06
P/FCF Ratio-0.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)€111.75K
Bulls Say, Bears Say
Bulls Say
Focused Precision-diagnostics OfferingProstatype’s core prognostic genomic test targets prostate cancer clinical decision-making, a structurally growing area in precision medicine. Durable demand from physicians and payers for actionable stratification can create steady per-test revenue and long-term clinical relevance if adoption expands.
Conservative Balance Sheet CushionModerate leverage and positive equity provide a structural cushion versus peers, reducing near-term solvency risk. This balance-sheet headroom supports the ability to raise targeted capital, pursue partnerships, or absorb losses while commercial scale is built, preserving optionality over months.
Lean Operating StructureA very small employee base indicates a lean fixed-cost profile and ability to leverage outsourced lab networks or partners. Structurally lower headcount makes incremental commercialization less capital intensive and can extend runway, improving odds of reaching scale if commercial traction improves.
Bears Say
Negative Gross Profit And Deep LossesNegative gross profit shows unit economics are currently broken; costs exceed revenue at the test level. Without sustained gross-margin recovery through pricing, cost reduction, or volume-driven efficiencies, operating losses cannot be meaningfully reduced, threatening long-term viability.
Recent Revenue DeclineA declining revenue trend in the core product undermines scaling and the path to profitability. With a small revenue base, further decreases magnify fixed-cost absorption problems and hinder achieving the volumes needed for sustainable margins and improved cash generation.
Persistent Cash Burn And Funding RelianceConsistent negative operating and free cash flow, and worsening FCF in 2025, imply ongoing reliance on external financing. That dependence risks dilution, restricts strategic investment in commercialization/validation, and is a material structural constraint if revenue recovery is delayed.
PGO0 FAQ
What was Prostatype Genomics AB’s price range in the past 12 months?
Prostatype Genomics AB lowest stock price was <€0.01 and its highest was €0.05 in the past 12 months.
What is Prostatype Genomics AB’s market cap?
Prostatype Genomics AB’s market cap is €7.76M.
When is Prostatype Genomics AB’s upcoming earnings report date?
Prostatype Genomics AB’s upcoming earnings report date is Aug 31, 2026 which is in 29 days.
How were Prostatype Genomics AB’s earnings last quarter?
Prostatype Genomics AB released its earnings results on Feb 26, 2026. The company reported -€0.014 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.014.
Is Prostatype Genomics AB overvalued?
According to Wall Street analysts Prostatype Genomics AB’s price is currently Overvalued.
Does Prostatype Genomics AB pay dividends?
Prostatype Genomics AB does not currently pay dividends.
What is Prostatype Genomics AB’s EPS estimate?
Prostatype Genomics AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Prostatype Genomics AB have?
Prostatype Genomics AB has 532,703,900 shares outstanding.
What happened to Prostatype Genomics AB’s price movement after its last earnings report?
Prostatype Genomics AB reported an EPS of -€0.014 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.846%.
Which hedge fund is a major shareholder of Prostatype Genomics AB?
Currently, no hedge funds are holding shares in DE:PGO0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Prostatype Genomics AB
Prostatype Genomics AB focuses on creating, marketing, and selling sophisticated prognostic gene tests. Their primary offering, the Prostatype Test System, combines genetic expression data with key clinical measurements such as PSA levels, Gleason Score, and Tumor Stage to determine a specific P-score. This advanced diagnostic tool is built upon a vast database of prostate cancer patients, providing crucial support for patients and medical practitioners when deciding on treatment strategies. Founded in 2007, the company is headquartered in Solna, Sweden.